ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Allergan's rapastinel fails to meet primary endpoints in Phase III depression studies
March 07, 2019Allergan on Wednesday announced topline results from the Phase III RAP-MD-01, RAP-MD-02 and RAP-MD-03 studies of the major depressive disorder (MDD) drug candidate rapastinel, saying treatment arms did not differentiate from placebo on the primary and key
Pharma Sources Insight January 2025
